Shanghai Securities News China Securities Network News (Reporter Luo Min) Fujilai disclosed abnormal fluctuations in stock trading and announced thatp0werballresultsyesterday, the company is concerned that some media, stock bar and other platforms discussed the company's business involving synthetic biology and related hot concepts. Biological enzymatic catalysis is the development trend for preparing R-lipoic acid. The company's biological enzymatic catalysis method has achieved mass production and is mainly used for external sales and preparation of R-lipoic acid sodium salt. It is still in the market promotion stage. Whether the original process can be completely replaced depends on many factors such as market demand and customer acceptance. In 2023, the company's income from such businesses will not exceed 3% of the company's operating income, which is relatively small, and there is no clear plan to expand production yet.